source
- FDA rejects ITM-11 radiopharmaceutical over manufacturing flaws, halting rival to Novartis therapyThe U.S. Food and Drug Administration issued a rejection letter for ITM-11, a radiopharmaceutical therapy developed by ITM Isotope Technologies Munich, citing manufacturing problems that prevent ap…
- Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular diseaseVaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program. The capital will support a newly launched Phase 3 study of the oral dr…